Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Hematological Malignancies Disease market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Hematological Malignancies Diseasemarket, defines the market attractiveness level of Hematological Malignancies Disease market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Hematological Malignancies Disease industry, describes the types of Hematological Malignancies Disease market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hematological Malignancies Disease market and the development prospects and opportunities of Hematological Malignancies Disease industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hematological Malignancies Disease market in Chapter 13.
By Player:
Takeda Pharma
Cancer Genetics Inc
NeoGenomics
AgenaBio
SkylineDx
Novartis
Signal Genetics
Regulus Therapeutics
MorphoSys
Ono Pharma
Rosetta Genomics
Abbott
Celgene
Exiqon
Affymetrix
Amgen
Mundipharma
Illumina
Sequenta
BMS
By Type:
Chemotherapy
Immunotherapy
Targeted Therapy
By End-User:
Leukemia
Lymphoma
Myeloma
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Hematological Malignancies Disease Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Hematological Malignancies Disease Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Hematological Malignancies Disease Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Hematological Malignancies Disease Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Hematological Malignancies Disease Market Analysis and Outlook to 2022
-
7.1 Global Hematological Malignancies Disease Consumption (2017-2022)
-
7.2 United States Hematological Malignancies Disease Consumption (2017-2022)
-
7.3 Europe Hematological Malignancies Disease Consumption (2017-2022)
-
7.4 China Hematological Malignancies Disease Consumption (2017-2022)
-
7.5 Japan Hematological Malignancies Disease Consumption (2017-2022)
-
7.6 India Hematological Malignancies Disease Consumption (2017-2022)
-
7.7 South Korea Hematological Malignancies Disease Consumption (2017-2022)
8 Region and Country-wise Hematological Malignancies Disease Market Analysis and Outlook to 2028
-
8.1 Global Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.2 United States Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.3 Europe Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.4 China Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.5 Japan Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.6 India Hematological Malignancies Disease Consumption Forecast (2022-2028)
-
8.7 South Korea Hematological Malignancies Disease Consumption Forecast (2022-2028)
9 Global Hematological Malignancies Disease Market Outlook by Types and Applications to 2022
-
9.1 Global Hematological Malignancies Disease Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Immunotherapy Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Targeted Therapy Consumption and Growth Rate (2017-2022)
-
9.2 Global Hematological Malignancies Disease Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Leukemia Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Lymphoma Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Myeloma Consumption and Growth Rate (2017-2022)
10 Global Hematological Malignancies Disease Market Outlook by Types and Applications to 2028
-
10.1 Global Hematological Malignancies Disease Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Hematological Malignancies Disease Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Myeloma Consumption Forecast and Growth Rate (2022-2028)
11 Global Hematological Malignancies Disease Import and Export Analysis (Top 5 Countries)
-
11.1 Global Hematological Malignancies Disease Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Hematological Malignancies Disease Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Hematological Malignancies Disease Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Hematological Malignancies Disease Market Competitive Analysis
-
14.1 Takeda Pharma
-
14.1.1 Takeda Pharma Company Details
-
14.1.2 Takeda Pharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Takeda Pharma Hematological Malignancies Disease Product and Service
-
14.2 Cancer Genetics Inc
-
14.2.1 Cancer Genetics Inc Company Details
-
14.2.2 Cancer Genetics Inc Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Cancer Genetics Inc Hematological Malignancies Disease Product and Service
-
14.3 NeoGenomics
-
14.3.1 NeoGenomics Company Details
-
14.3.2 NeoGenomics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 NeoGenomics Hematological Malignancies Disease Product and Service
-
14.4 AgenaBio
-
14.4.1 AgenaBio Company Details
-
14.4.2 AgenaBio Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 AgenaBio Hematological Malignancies Disease Product and Service
-
14.5 SkylineDx
-
14.5.1 SkylineDx Company Details
-
14.5.2 SkylineDx Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 SkylineDx Hematological Malignancies Disease Product and Service
-
14.6 Novartis
-
14.6.1 Novartis Company Details
-
14.6.2 Novartis Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Novartis Hematological Malignancies Disease Product and Service
-
14.7 Signal Genetics
-
14.7.1 Signal Genetics Company Details
-
14.7.2 Signal Genetics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Signal Genetics Hematological Malignancies Disease Product and Service
-
14.8 Regulus Therapeutics
-
14.8.1 Regulus Therapeutics Company Details
-
14.8.2 Regulus Therapeutics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Regulus Therapeutics Hematological Malignancies Disease Product and Service
-
14.9 MorphoSys
-
14.9.1 MorphoSys Company Details
-
14.9.2 MorphoSys Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 MorphoSys Hematological Malignancies Disease Product and Service
-
14.10 Ono Pharma
-
14.10.1 Ono Pharma Company Details
-
14.10.2 Ono Pharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Ono Pharma Hematological Malignancies Disease Product and Service
-
14.11 Rosetta Genomics
-
14.11.1 Rosetta Genomics Company Details
-
14.11.2 Rosetta Genomics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Rosetta Genomics Hematological Malignancies Disease Product and Service
-
14.12 Abbott
-
14.12.1 Abbott Company Details
-
14.12.2 Abbott Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Abbott Hematological Malignancies Disease Product and Service
-
14.13 Celgene
-
14.13.1 Celgene Company Details
-
14.13.2 Celgene Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Celgene Hematological Malignancies Disease Product and Service
-
14.14 Exiqon
-
14.14.1 Exiqon Company Details
-
14.14.2 Exiqon Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Exiqon Hematological Malignancies Disease Product and Service
-
14.15 Affymetrix
-
14.15.1 Affymetrix Company Details
-
14.15.2 Affymetrix Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.15.3 Affymetrix Hematological Malignancies Disease Product and Service
-
14.16 Amgen
-
14.16.1 Amgen Company Details
-
14.16.2 Amgen Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.16.3 Amgen Hematological Malignancies Disease Product and Service
-
14.17 Mundipharma
-
14.17.1 Mundipharma Company Details
-
14.17.2 Mundipharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.17.3 Mundipharma Hematological Malignancies Disease Product and Service
-
14.18 Illumina
-
14.18.1 Illumina Company Details
-
14.18.2 Illumina Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.18.3 Illumina Hematological Malignancies Disease Product and Service
-
14.19 Sequenta
-
14.19.1 Sequenta Company Details
-
14.19.2 Sequenta Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.19.3 Sequenta Hematological Malignancies Disease Product and Service
-
14.20 BMS
-
14.20.1 BMS Company Details
-
14.20.2 BMS Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
14.20.3 BMS Hematological Malignancies Disease Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Hematological Malignancies Disease
-
Figure Hematological Malignancies Disease Picture
-
Table Global Hematological Malignancies Disease Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hematological Malignancies Disease Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Hematological Malignancies Disease Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Hematological Malignancies Disease Consumption by Country (2017-2022)
-
Figure United States Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Table Europe Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Figure China Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Figure Japan Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Figure India Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Figure South Korea Hematological Malignancies Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Hematological Malignancies Disease Consumption Forecast by Country (2022-2028)
-
Figure United States Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Hematological Malignancies Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Immunotherapy Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Leukemia Consumption and Growth Rate (2017-2022)
-
Figure Global Lymphoma Consumption and Growth Rate (2017-2022)
-
Figure Global Myeloma Consumption and Growth Rate (2017-2022)
-
Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunotherapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Leukemia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Myeloma Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Hematological Malignancies Disease Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Hematological Malignancies Disease Export by Region (Top 5 Countries) (2017-2028)
-
Table Takeda Pharma (Foundation Year, Company Profile and etc.)
-
Table Takeda Pharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharma Hematological Malignancies Disease Product and Service
-
Table Cancer Genetics Inc (Foundation Year, Company Profile and etc.)
-
Table Cancer Genetics Inc Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cancer Genetics Inc Hematological Malignancies Disease Product and Service
-
Table NeoGenomics (Foundation Year, Company Profile and etc.)
-
Table NeoGenomics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table NeoGenomics Hematological Malignancies Disease Product and Service
-
Table AgenaBio (Foundation Year, Company Profile and etc.)
-
Table AgenaBio Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table AgenaBio Hematological Malignancies Disease Product and Service
-
Table SkylineDx (Foundation Year, Company Profile and etc.)
-
Table SkylineDx Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table SkylineDx Hematological Malignancies Disease Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Hematological Malignancies Disease Product and Service
-
Table Signal Genetics (Foundation Year, Company Profile and etc.)
-
Table Signal Genetics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Signal Genetics Hematological Malignancies Disease Product and Service
-
Table Regulus Therapeutics (Foundation Year, Company Profile and etc.)
-
Table Regulus Therapeutics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Regulus Therapeutics Hematological Malignancies Disease Product and Service
-
Table MorphoSys (Foundation Year, Company Profile and etc.)
-
Table MorphoSys Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table MorphoSys Hematological Malignancies Disease Product and Service
-
Table Ono Pharma (Foundation Year, Company Profile and etc.)
-
Table Ono Pharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ono Pharma Hematological Malignancies Disease Product and Service
-
Table Rosetta Genomics (Foundation Year, Company Profile and etc.)
-
Table Rosetta Genomics Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Rosetta Genomics Hematological Malignancies Disease Product and Service
-
Table Abbott (Foundation Year, Company Profile and etc.)
-
Table Abbott Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Hematological Malignancies Disease Product and Service
-
Table Celgene (Foundation Year, Company Profile and etc.)
-
Table Celgene Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Hematological Malignancies Disease Product and Service
-
Table Exiqon (Foundation Year, Company Profile and etc.)
-
Table Exiqon Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Exiqon Hematological Malignancies Disease Product and Service
-
Table Affymetrix (Foundation Year, Company Profile and etc.)
-
Table Affymetrix Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Affymetrix Hematological Malignancies Disease Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Hematological Malignancies Disease Product and Service
-
Table Mundipharma (Foundation Year, Company Profile and etc.)
-
Table Mundipharma Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mundipharma Hematological Malignancies Disease Product and Service
-
Table Illumina (Foundation Year, Company Profile and etc.)
-
Table Illumina Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Illumina Hematological Malignancies Disease Product and Service
-
Table Sequenta (Foundation Year, Company Profile and etc.)
-
Table Sequenta Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sequenta Hematological Malignancies Disease Product and Service
-
Table BMS (Foundation Year, Company Profile and etc.)
-
Table BMS Hematological Malignancies Disease Sales, Price, Value and Gross Profit (2017-2022)
-
Table BMS Hematological Malignancies Disease Product and Service
-
